INTRODUCTION

BINTAC contains Ranitidine which belongs to a group of medicines called H2 receptor antagonists. It acts by reducing the amount of acid produced in your stomach. It is indicated for the treatment of duodenal ulcer, benign gastric ulcer, reflux esophagitis, post-operative peptic ulcer, Zollinger-Ellison Syndrome and other conditions where reduction of gastric secretion and acid output is desirable. It also heals and stop problems caused by heartburn (acid in the food pipe) or indigestion. It can also be used for the prophylaxis and maintenance treatment of duodenal or benign gastric ulcer in patients with a history of recurrent ulceration.

Ranitidine reduces the secretion of gastric acid stimulated either by food or drugs like non-steroidal anti-inflammatories (NSAIDs), often used to treat arthritis. It reduces gastric acid production by reversibly binding to histamine (H2) receptors present in the lining of gastric parietal cells. It inhibits both basal gastric secretion and gastric acid secretion induced by histamine, pentagastrin and other secretagogues.

Along with this treatment, your doctor might recommend you, to take enough rest and drink plenty of fluids. Sticking to simple meals and avoiding rich or spicy food can also be beneficial. Avoid smoking and consumption of alcohol during this therapy, as it may reduce the chances of healing and worsen the ulcers. The most common side effects of taking this medicine are stomach pain, constipation or nausea, although not everybody gets them. Before taking this medicine, inform your doctor if you have stomach cancer, kidney problems, porphyria or diabetes. BINTAC should not be taken during pregnancy or while breast-feeding unless considered essential by your doctor.

USES OF BINTAC

• Used in the treatment of stomach and duodenal ulcers, heartburn (acid in the food pipe) and indigestion in both adults and in children above 3 years of age
• Stops acid reflux, while under anesthesia during an operation

HOW BINTAC WORKS

Ranitidine causes reversible binding to histamine (H2) receptors present in the lining of gastric parietal cells. Binding of histamine to H2 receptors triggers the production of stomach pain. Ranitidine selectively and competitively antagonizes the effects of histamine at H2-receptors and reduces the secretion of gastric acid. It also inhibits gastric acid secretion induced by pentagastrin and other secretagogues.

DIRECTIONS FOR USE

This medicine should always be administered by a physician or a nurse into the vein (intravenously) or muscle (intramuscularly). Your doctor will decide the correct dose and duration of therapy depending upon your age, weight and disease condition.

SIDE EFFECTS OF BINTAC

HOW TO MANAGE SIDE EFFECTS

Feeling sick (nausea):

Try taking this medicine with, or just after, a meal. Stick to simple meals. Do not eat rich or spicy food.

Constipation: 

Eat fibre rich foods like fresh fruit, vegetables and cereals. Drink plenty of water. Exercise more regularly.

Stomach pain:

Try to rest and relax. You can eat and drink slowly or have smaller and frequent meals. Keeping a heat pad on your stomach may also help. If still pain persists, speak to your doctor.

WARNING & PRECAUTIONS

INTERACTIONS

Talk to your doctor, if you are taking,

• medicines used to treat diabetes (e.g. glipizide or glibenclamide)
• medicines used to treat heart problems (e.g. procainamide, N-acetylprocainamide or propranolol)
• medicines used to induce sleep (e.g. triazolam or midazolam)
• medicines used to treat infections (e.g. raltegravir, atazanavir, delavirdine, ketoconazole, itraconazole or cefpodoxime)
• medicines used to treat cancer (e.g. gefitinib or lapatinib)
• warfarin (used to stop blood clots)
• lidocaine (a local anaesthetic)
• diazepam (used to treat anxiety)
• phenytoin (used to treat epilepsy)
• theophylline (used to treat long term breathing problems)

SYNOPSIS

MORE INFORMATION

Store below 20-25°C and keep out of reach of children.

FAQs ABOUT BINTAC

Can BINTAC cause nausea?

Yes. It may cause nausea in some individuals, although not everybody gets them. Try taking this medicine with, or just after, a meal. Stick to simple meals. Do not eat rich or spicy food.

Is BINTAC suitable for children?

Yes. It is suitable for use in children aged above 3 years. Your doctor will decide the dose and duration of therapy depending upon your child’s age and weight.

Can BINTAC be taken during pregnancy?

It should not be taken during pregnancy unless considered essential by your doctor. Discuss the risks and benefits with your doctor.

REFERENCES

1. KD. Tripathi. Drugs for Peptic ulcer and Gastroesophageal Reflux Disease. Essentials of medical pharmacology. Seventh edition. 2013. Page – 649-650.

2. John L. Wallace and Keith A. Sharkey. Pharmacotherapy of Gastric acidity, Peptic ulcer and Gastroesophageal Reflux disease. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 12th Edition. New York McGraw Hill Medical 2011. Page – 1313-1314.

3. Gerald G. Briggs and Roger K. Freeman. R. A reference guide to fetal and neonatal risk: Drugs in Pregnancy and Lactation. Tenth Edition. 2015. Page – 3356-2775.

4. Van Rensburg C, Barkun AN, Racz I, Fedorak R, Bornman PC, Beglinger C, Balanzo J, Deviere J, Kupcinskas L, Luehmann R, Doerfler H, Schafer-Preuss S. Tygerberg Academic Hospital, University of Stellenbosch. Clinical trial: intravenous pantoprazole vs. ranitidine for the prevention of peptic ulcer rebleeding: a multicentre, multinational, randomized trial. DrugLib.com. January 2009. [Accessed 24th November 2020] http://www.druglib.com/abstract/va/van-rensburg-c_aliment-pharmacol-ther_20090301.html

5. C van Rensburg, A N Barkun, I Racz, R Fedorak, P C Bornman, C Beglinger, J Balanzó, J Devière, L Kupcinskas, R Luehmann, H Doerfler, S Schäfer-Preuss. Clinical trial: intravenous pantoprazole vs. ranitidine for the prevention of peptic ulcer rebleeding: a multicentre, multinational, randomized trial. NIH National Library of Medicine, National center for biotechnology information. Pubmed.gov. [Revised on March 2009] [Accessed 24th November 2020] https://pubmed.ncbi.nlm.nih.gov/19053987/

6. G Brunner, J Chang. Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: an open randomized controlled trial. NIH National Library of Medicine, National center for biotechnology information. Pubmed.gov. [Revised on 1990] [Accessed 24th November 2020] https://pubmed.ncbi.nlm.nih.gov/2205527/

7. Kleva S A. Electronic Medicines Compendium (EMC); [Revised on May 2016] [Accessed 24th November 2020] https://www.medicines.org.uk/emc/files/pil.4453.pdf

8. GlaxoSmithKline. U.S. Food & Drug Administration. [Revised on April 2009] [Accessed 24th November 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019090s053,019593s042lbl.pdf

9. Glaxo Wellcome Inc. U.S. Food & Drug Administration. [Revised on November 1999] [Accessed 24th November 2020] https://www.accessdata.fda.gov/drugsatfda_docs/label/1999/019593s028lbl.pdf